NCT01636882View on ClinicalTrials.gov

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 3, 2012

Primary Completion Date

April 6, 2016

Study Completion Date

April 6, 2016

Conditions
Melanoma
Interventions
BIOLOGICAL

CVA21

Trial Locations (4)

60714

Oncology Specialists, Park Ridge

75230

Mary Crowley Medical Center, Dallas

84112

Huntsman Cancer Institute, Salt Lake City

97213

Providence Medical Centre, Portland

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT01636882 - CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) | Biotech Hunter | Biotech Hunter